Hologic (HOLX) PT, Estimates Raised at Jefferies Post Q2

Go back to Hologic (HOLX) PT, Estimates Raised at Jefferies Post Q2

Hologic (HOLX) Buy Reiterated a Needham & Company Post Q2 on 'Encouraging' Return to Rev Growth

May 1, 2014 7:15 AM EDT

Needham & Company analyst Mike Matson reiterated a Buy rating and $26 price target on Hologic (NASDAQ: HOLX) following Q2 results which showed an 'encouraging' return to positive revenue growth.

Matson comments, "HOLX's F2Q14 results were well above consensus. Revenue upside was driven... More

Hologic, Inc. (HOLX) Tops Q2 EPS by 4c

April 30, 2014 4:02 PM EDT

Hologic, Inc. (NASDAQ: HOLX) reported Q2 EPS of $0.37, $0.04 better than the analyst estimate of $0.33. Revenue for the quarter came in at $625 million versus the consensus estimate of $609.35 million.

"Second quarter results reflect early progress towards our renewed focus on executional... More